GSK's Paxil plant cited in warning letter

Share this article:
GSK misses on late-stage CV drug
GSK’s Paxil plant cited in warning letter

GlaxoSmithKline got some unwelcome attention from the FDA inspectors: a March 27 warning letter about unacceptable manufacturing and communications at a Cork, Ireland, manufacturing site where it found contamination issues. The letter notes that this is not the first time the regulator has asked about this plant, and that the firm's initial response "lacks sufficient corrective actions."

Dublin-based news website RTE reports that the plant made active ingredients for the anti-depressant Paxil and has since recalled batches of the drug.

The FDA notes that failure to provide an adequate response and fixes may prompt the US agency to ban materials produced at this site, which uses the company name SmithKline Beecham.

The FDA's list of grievances includes accusations that the drugmaker distributed products even after it knew items could have been contaminated.

The FDA noted that although GSK's own communications requirements indicate the company has to tell customers about possible deviations, like the potentially contaminated product, it failed to do so at the time. “We are concerned that your firm does not consider the entry of pharmaceutical waste streams into your manufacturing process a significant deviation with a potential quality impact,” the agency wrote.

The FDA also calls out the manufacturer for ignoring red flags that exist to indicate contamination. It noted that two gas chromatic analyses—a test that can spot problems—“show large peaks... as well as small but detectable levels of at least 10 other contaminants,” but GSK did nothing about warnings. The FDA also says the company response does not explain why its analysts did not see these contamination signals.

Additional concerns include the site's failure to use consecutive testing batches.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.